The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage
Abstract
BACKGROUND: Conflicting findings with regard to the teratogenic risks of first trimester use of paroxetine have prompted the FDA, Health Canada, and the manufacturer of the drug to issue warnings against its use during pregnancy. Given that untreated depression during pregnancy can lead to deleterious effect on the mother and her unborn fetus, data on the relationship between the dose and the range of malformations is warranted. This study attempts to quantify the association between first trimester exposure to paroxetine and congenital cardiac malformations, adjusting for possible confounders, and to quantify the dose–response relationship between paroxetine use and cardiac defects. METHODS: The Medication and Pregnancy registry was used. This population‐based registry was built by linking three administrative databases (RAMQ, Med‐Écho, and ISQ), and includes all pregnancies in Quebec between 01/01/1997 and 06/30/2003. Date of entry in the registry is the date of the first day of the last menstrual period. To be eligible for this study, women had to: 1) be 15–45 years of age at entry; 2) be covered by the RAMQ drug plan ≥12 months before and during pregnancy; 3) be using only one type of antidepressant during the first trimester; and 4) have a live birth. Two nested case‐control studies were carried out comparing the prevalence of paroxetine use in the first trimester of pregnancy to the prevalence of other antidepressant exposures during the same time period. Cases were defined as: 1) any major malformations; or 2) any cardiac malformations diagnosed in the first year of life; controls were defined as no major or minor malformations. Multivariate logistic regression techniques were used to analyze data. RESULTS: Among the 1,403 women meeting inclusion criteria, 101 infants with major congenital malformations were identified; 24 had cardiac malformations. Adjusting for possible confounders, the use of paroxetine (odds ratio [OR] = 1.38, 95% confidence interval [CI] = 0.49–3.92), and the use of other SSRIs (OR = 0.89, 95% CI = 0.28–2.84) during the first trimester of pregnancy did not increase the risk of congenital cardiac malformations compared with the use of non‐SSRI antidepressants. When considering the dose, however, a dose–response relationship was observed, thus women exposed to >25 mg/day of paroxetine during the first trimester of pregnancy were at increased risk of having an infant with major congenital malformations (adjusted [adj] OR = 2.23, 95% CI = 1.19, 4.17), or major cardiac malformations (adj OR = 3.07, 95% CI = 1.00, 9.42). CONCLUSIONS: Gestational exposure to paroxetine is associated with major congenital malformations and major cardiac malformations for only first trimester exposure above 25 mg/day. Birth Defects Res (Part B). © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Czeizel, A. E., & Dudás, I. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212243272602 · Cited by 3,178
The course of anxiety and depression through pregnancy and the postpartum in a community sample
Heron, J., O'Connor, T. G., Evans, J., Golding, J., & Glover, V. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.08.004 · Cited by 1,151
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Persistence of Use of Lipid-Lowering Medications: A Cross-National Study
Avorn, J., Monette, J., Lacour, A., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 634
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
Tobacco smoking and oral clefts: a meta-analysis.
Little, J., Cardy, A. H., & Munger, R. G. (2004) · Europe PMC (PubMed Central) · Cited by 394
Drugs in Pregnancy and Lactation
BRIGGS, G. G., FREEMAN, R. K., & YAFFE, S. J. (1987) · MCN, The American Journal of Maternal/Child Nursing · doi:10.1097/00005721-198711000-00013 · Cited by 386
Mortality in a cohort of street youth in Montreal
Roy, É. (2004) · JAMA · doi:10.1001/jama.292.5.569 · Cited by 334
Blais, L., Desgagné, A., & LeLorier, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2363 · Cited by 326
Self-citationNeonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy
Källén, B. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.4.312 · Cited by 300
Cited by
Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
Alwan, S., Reefhuis, J., Rasmussen, S. A., Olney, R. S., & Friedman, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066584 · Cited by 495
Gentile, S. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.001 · Cited by 434
Use of antidepressant medications during pregnancy: a multisite study
Andrade, S. E., Raebel, M. A., Brown, J., Lane, K., Livingston, J., Boudreau, D., Rolnick, S. J., Roblin, D., Smith, D. H., Willy, M. E., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.07.036 · Cited by 403
Antidepressant Use in Pregnancy and the Risk of Cardiac Defects
Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312828 · Cited by 402
Reis, M., & Källén, B. (2010) · Psychological Medicine · doi:10.1017/s0033291709992194 · Cited by 340
Pedersen, L. H., Henriksen, T. B., Vestergaard, M., Olsen, J., & Bech, B. H. (2009) · BMJ · doi:10.1136/bmj.b3569 · Cited by 297
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.684 · Cited by 268
Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors
Suri, D., Teixeira, C. M., Cagliostro, M. K. C., Mahadevia, D., & Ansorge, M. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.231 · Cited by 167
Bakker, M. K., Kölling, P., Van Den Berg, P. B., De Walle, H. E. K., & De Jong van den Berg, L. T. W. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03048.x · Cited by 158
National trends in antidepressant medication treatment among publicly insured pregnant women
Huybrechts, K. F., Palmsten, K., Mogun, H., Kowal, M., Avorn, J., Setoguchi-Iwata, S., & Hernández-Díaz, S. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.12.010 · Cited by 161
Antidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
Patterns of antidepressant medication use among pregnant women in a United States population
Alwan, S., Reefhuis, J., Rasmussen, S. A., Friedman, J. M., & Study, N. B. D. P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010373928 · Cited by 149
Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret, C., Isaac, M., & Briley, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093582 · Cited by 135
Antidepressants in pregnancy: a systematic review.
(2010) · PubMed · doi:10.3109/00048674.2010.507543 · Cited by 128
Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort Study
Jimenez-Solem, E., Andersen, J. T., Petersen, M., Broedbaek, K., Andersen, N. L., Torp-Pedersen, C., & Poulsen, H. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063034 · Cited by 119
Tuccori, M., Testi, A., Antonioli, L., Fornai, M., Montagnani, S., Ghisu, N., Colucci, R., Corona, T., Blandizzi, C., & Tacca, M. D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.009 · Cited by 95
The effect of perinatal exposures on the infant: Antidepressants and depression
Hanley, G. E., & Oberlander, T. F. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.09.001 · Cited by 56
New insights into how serotonin selective reuptake inhibitors shape the developing brain
Gingrich, J. A., Malm, H., Ansorge, M. S., Brown, A., Sourander, A., Suri, D., Teixeira, C. M., Caffrey Cagliostro, M. K., Mahadevia, D., & Weissman, M. M. (2017) · Birth Defects Research · doi:10.1002/bdr2.1085 · Cited by 53
Molenaar, N. M., Lambregtse-van den Berg, M. P., & Bonsel, G. J. (2020) · Archives of Women's Mental Health · doi:10.1007/s00737-019-0951-5 · Cited by 30
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
Metadata
- Authors
- Bérard, A., Ramos, É., Rey, É., Blais, L., St.‐André, M., & Oraichi, D.
- Venue
- Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Publisher
- Wiley
- Published
- 2006-12-22
- Volume
- 80
- Issue
- 1
- Pages
- 18-27
- ISSN
- 1542-9733 (ISSN-L)
- 1542-9741
- OpenAlex
- W2086694416
- Cited by
- 275
- References
- 20
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.